Mtor Inhibitor Mln0128
Mtor Inhibitor Mln0128 - Related Videos
03:03
mTOR Signaling and Cancer Progression
0 Views •
2023
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:03
mTOR Signaling and Cancer Progression
0 Views •
2021
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
01:22
PI3K/mTOR/AKT Signaling Pathway
0 Views •
2023
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:52
Eukaryotic Transcription Inhibitors
0 Views •
2020
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells. Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
04:00
Modelling Intratumoral Treatment with miRNA Inhibitors: A Method to Analyze the Effect of miRNA Inhibitors on Tumor Growth in Murine Model
0 Views •
2023
This video demonstrates the in vivo delivery of miRNA inhibitors as therapeutic agents against tumor growth in orthotopic mouse models. The intratumoral administration of synthetic miRNA inhibitors or antagomiRs allows them to bind and inhibit endogenous miRNAs, thereby causing mRNA upregulation and suppression of tumor growth.
FAQs
Because MLN0128 inhibits both mTOR complex 1 and mTOR complex 2, experiments can assess the consequences of broader pathway blockade rather than effects linked to only one complex. Reduced phosphorylation of downstream signaling proteins then provides a molecular readout connecting mTOR inhibition with changes in protein synthesis, proliferation, and survival in cancer models.
Phosphorylation of downstream signaling proteins is a key indicator of pathway response. Researchers can relate changes in these signals to protein synthesis, cell proliferation, and survival, allowing molecular effects to be considered alongside tumor-cell behavior. This connection helps clarify whether MLN0128 produces pathway blockade associated with reduced malignant growth or survival.
MLN0128 helps researchers examine whether blocking mTOR signaling alters the cellular responses associated with resistance to therapy. By measuring pathway-related phosphorylation together with effects on proliferation and survival, studies can investigate how mTOR blockade influences treatment response. These findings may support evaluation of targeted strategies designed to address resistant cancer-cell behavior.
A preclinical study can use MLN0128 to test how mTOR pathway blockade affects tumor-cell growth and survival. Researchers examine the resulting molecular and cellular changes, then compare those findings with the intended treatment strategy. This approach supports mechanistic studies before evaluating targeted treatment concepts in broader experimental designs.
The compound can provide both signaling and cellular outcomes. Changes in phosphorylation of downstream proteins indicate effects on mTOR pathway activity, while altered protein synthesis, proliferation, or survival reflects functional consequences in tumor cells. Considering these levels together helps researchers connect pathway inhibition with the biological behavior observed in cancer models.
MLN0128 is particularly relevant when a study asks whether mTOR pathway blockade can complement another anticancer agent. Preclinical combinations can be examined for effects on tumor-cell growth, survival, and therapy resistance, while downstream phosphorylation changes help interpret the mechanism. Such work supports the development and evaluation of targeted treatment strategies.